Get the Stockscreener App
1.93
0.00%
0.00
Pre-market:
1.96
0.03
+1.55%
Nrx Pharmaceuticals Inc stock is traded at $1.93, with a volume of 63,423.
It is up +0.00% in the last 24 hours and down -5.85% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.93
Open:
$1.94
24h Volume:
63,423
Relative Volume:
0.18
Market Cap:
$34.34M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.4825
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
+7.82%
1M Performance:
-5.85%
6M Performance:
+52.57%
1Y Performance:
-53.83%
1-Day Range:
$1.89
$1.96
1-Week Range:
$1.80
$2.14
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
1.93 | 34.34M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals CEO Sets to Reveal Growth Strategy at Exclusive H.C. Wainwright Discussion - Stock Titan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics (PR Newswire) - Aktiellt
NRx Pharmaceuticals increases at-the-market offering to $20M - Investing.com Australia
NRx Pharmaceuticals increases at-the-market offering to $20M By Investing.com - Investing.com Canada
Press Release Distribution & PR Platform - ACCESS Newswire
HOPE Therapeutics secures $2.5 million investment By Investing.com - Investing.com South Africa
Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD with Groundbreaking Drugs and Modalities: $NRXP - The Globe and Mail
Hope Therapeutics And Nrx Pharma Announce Signing Of A Term Sheet For Strategic Investment From A Global Medical Device Manufacturer - MarketScreener
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE - Morningstar
BTIG Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation - Nasdaq
BTIG initiates NRx Pharmaceuticals with $18 price target By Investing.com - Investing.com Australia
BTIG initiates NRx Pharmaceuticals with $18 price target - Investing.com
HOPE Therapeutics expands with Dura Medical acquisition By Investing.com - Investing.com Canada
NRx Pharmaceuticals' Hope Therapeutics to acquire Dura Medical, no terms - MSN
NRx Pharma: HOPE Therapeutics Signs Deal To Buy Dura Medical - Nasdaq
HOPE Therapeutics expands with Dura Medical acquisition - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics - Longview News-Journal
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now - MSN
HOPE Therapeutics set to acquire majority of Neurospa By Investing.com - Investing.com Australia
$300 Million in Milestones; Double-Digit Royalties; LOI with - openPR.com
NRx Pharmaceuticals Unit Signs Letter of Intent to Acquire Neurospa TMS -March 24, 2025 at 08:43 am EDT - MarketScreener
HOPE Therapeutics and NRx Pharmaceuticals Sign Binding Letter of Intent with Neurospa TMS Holdings - MarketScreener
HOPE Therapeutics set to acquire majority of Neurospa - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics - Longview News-Journal
NRX Pharmaceuticals Reports 2024 Financial Results and Strategy - TipRanks
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains $19 target on NRx Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $19 target on NRx Pharmaceuticals stock - Investing.com
NRx Pharmaceuticals submits NDA for intravenous ketamine drug - Mugglehead Magazine
NRx pharmaceuticals files New Drug Application for ketamine depression treatment - Green Market Report
NRx Pharmaceuticals (NRXP) to Release Quarterly Earnings on Wednesday - Defense World
NRX Pharmaceuticals Inc (NRXP) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... By GuruFocus - Investing.com Canada
NRx Pharmaceuticals Reports Progress in Drug Development and Strategic Expansion - TipRanks
NRx Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart
$300 Million in Milestones Plus Tiered Double-Digit Royalties - openPR
Earnings call transcript: NRx Pharmaceuticals sees stock dip despite cost cuts in Q4 2024 By Investing.com - Investing.com South Africa
NRX Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: NRx Pharmaceuticals sees stock dip despite cost cuts in Q4 2024 - Investing.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
INVESTOR ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm - ACCESS Newswire
NRX Pharmaceuticals, Inc. SEC 10-K Report - TradingView
NRX Pharmaceuticals Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):